Journal article
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders
Abstract
BACKGROUND & AIMS: Differences in 1-year outcomes among early compared with delayed responders to vedolizumab have been shown in ulcerative colitis. However, it is unclear whether similar differences exist with ustekinumab, and what factors differentiate delayed responders from nonresponders.
METHODS: This study was a post hoc analysis of patient-level data from the UNIFI clinical trial. Ustekinumab-treated patients with clinical response, …
Authors
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Journal
Clinical Gastroenterology and Hepatology, Vol. 21, No. 13, pp. 3387–3396.e1
Publisher
Elsevier
Publication Date
December 2023
DOI
10.1016/j.cgh.2023.06.011
ISSN
1542-3565